AmCad BioMed

AmCad BioMed EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of AmCad BioMed (4188.TWO) as of Nov 5, 2026 is -87.96 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -64.66 M TWD — a change of 36.02% (lower).

EBITDA

-87.96 MTWD

YoY

36.02%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of AmCad BioMed is 2025 -87.96 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of AmCad BioMed was 2024 -64.66 M TWD. It decreases by 36.02% lower compared to the previous year.

The AmCad BioMed EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-80.09 M TWD
Jan 1, 2019
-56.29 M TWD
Jan 1, 2020
-42.84 M TWD
Jan 1, 2021
-26.85 M TWD
Jan 1, 2022
-54.28 M TWD
Jan 1, 2023
-43.03 M TWD
Jan 1, 2024
-64.66 M TWD
Jan 1, 2025
-87.96 M TWD
The AmCad BioMed EBITDA history
YEAREBITDAYoY
-87.96 MTWD+36.02%
-64.66 MTWD+50.29%
-43.03 MTWD-20.73%
-54.28 MTWD+102.18%
-26.85 MTWD-37.33%
-42.84 MTWD-23.90%
-56.29 MTWD-29.72%
-80.09 MTWD+25.10%
-64.03 MTWD+7.55%
-59.53 MTWD-7.03%
-64.03 MTWD+41.49%
-45.26 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

AmCad BioMed Stock analysis

What does AmCad BioMed do? AmCad BioMed Corp, headquartered in Taipei City, Taiwan, specializes in manufacturing and selling medical diagnostic software devices. The company offers products like AmCAT-UT Detection, a computer-aided detection system for thyroid ultrasound, and AmCAD-UT Diagnosis, a computer-aided diagnosis system for the same purpose. Listed on 26 December 2013, AmCad BioMed operates in Taiwan, China, and Hong Kong markets. AmCad BioMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AmCad BioMed stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of AmCad BioMed is -87.96 M TWD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of AmCad BioMed changed from -64.66 M TWD to -87.96 M TWD, representing a 36.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) AmCad BioMed since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s AmCad BioMed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — AmCad BioMed

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — AmCad BioMed